View in EDS

Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.

Saved in:
Bibliographic Details
Title: Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.
Authors: Mendes D; Pfizer Ltd, Tadworth, UK., Averin A; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Atwood M; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Sato R; Pfizer Inc, Collegeville, PA, USA., Vyse A; Pfizer Ltd, Tadworth, UK., Campling J; Pfizer Ltd, Tadworth, UK., Weycker D; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA., Slack M; School of Medicine & Dentistry, Griffith University, Gold Coast Campus, 4222, Australia., Ellsbury G; Pfizer Ltd, Tadworth, UK., Mugwagwa T; Pfizer Ltd, Tadworth, UK.
Source: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2022 Dec; Vol. 22 (8), pp. 1285-1295. Date of Electronic Publication: 2022 Nov 03.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101132257 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8379 (Electronic) Linking ISSN: 14737167 NLM ISO Abbreviation: Expert Rev Pharmacoecon Outcomes Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36225103
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mendes+D%22">Mendes D</searchLink>; Pfizer Ltd, Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Averin+A%22">Averin A</searchLink>; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA.<br /><searchLink fieldCode="AU" term="%22Atwood+M%22">Atwood M</searchLink>; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sato+R%22">Sato R</searchLink>; Pfizer Inc, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Vyse+A%22">Vyse A</searchLink>; Pfizer Ltd, Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Campling+J%22">Campling J</searchLink>; Pfizer Ltd, Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Weycker+D%22">Weycker D</searchLink>; Policy Analysis Inc. (PAI), Chestnut Hill, MA, USA.<br /><searchLink fieldCode="AU" term="%22Slack+M%22">Slack M</searchLink>; School of Medicine & Dentistry, Griffith University, Gold Coast Campus, 4222, Australia.<br /><searchLink fieldCode="AU" term="%22Ellsbury+G%22">Ellsbury G</searchLink>; Pfizer Ltd, Tadworth, UK.<br /><searchLink fieldCode="AU" term="%22Mugwagwa+T%22">Mugwagwa T</searchLink>; Pfizer Ltd, Tadworth, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132257%22">Expert review of pharmacoeconomics & outcomes research</searchLink> [Expert Rev Pharmacoecon Outcomes Res] 2022 Dec; Vol. 22 (8), pp. 1285-1295. <i>Date of Electronic Publication: </i>2022 Nov 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101132257 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8379 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214737167%22">14737167 </searchLink><i>NLM ISO Abbreviation: </i>Expert Rev Pharmacoecon Outcomes Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36225103
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14737167.2022.2134120
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1285
    Titles:
      – TitleFull: Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mendes D
      – PersonEntity:
          Name:
            NameFull: Averin A
      – PersonEntity:
          Name:
            NameFull: Atwood M
      – PersonEntity:
          Name:
            NameFull: Sato R
      – PersonEntity:
          Name:
            NameFull: Vyse A
      – PersonEntity:
          Name:
            NameFull: Campling J
      – PersonEntity:
          Name:
            NameFull: Weycker D
      – PersonEntity:
          Name:
            NameFull: Slack M
      – PersonEntity:
          Name:
            NameFull: Ellsbury G
      – PersonEntity:
          Name:
            NameFull: Mugwagwa T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2022 Dec
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8379
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Expert review of pharmacoeconomics & outcomes research
              Type: main
ResultId 1